MISSISSAUGA, Ontario, Nov. 17, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. ("BioSyent", TSX Venture: RX) released today its consolidated financial results for the three months (Q3), nine months (YTD), and trailing twelve months (TTM) ended September 30, 2026. Key highlights include:
% Change % Change % Change
vs. Q3 vs. YTD TTM Sep vs. TTM Sep
(CAD) Q3 2026 2025 YTD 2026 2025 30, 2026 30, 2025
--------------- ---------- ---------- ---------- ---------- ---------- -----------
Pharmaceutical
Sales 11,530,182 +5% 33,443,654 +6% 42,837,694 +7%
Oral Health
Sales 7,814,229 n/a 19,023,604 n/a 19,023,604 n/a
Insecticide
Sales 740,176 -39% 1,398,274 -26% 1,676,157 -15%
--------------- ---------- ---- --- ---------- ---- --- ---------- --- -----
Total Company
Sales 20,084,587 +64% 53,865,532 +61% 63,537,455 +51%
--------------- ---------- ---- --- ---------- ---- --- ---------- --- -----
EBITDA(1) 5,572,805 +53% 14,188,144 +48% 16,716,705 +41%
--------------- ---------- ---- --- ---------- ---- --- ---------- --- -----
Net Income
After Taxes
(NIAT) 2,860,465 +7% 8,054,721 +15% 10,046,509 +16%
--------------- ---------- ---- --- ---------- ---- --- ---------- --- -----
Fully Diluted
EPS 0.25 +8% 0.70 +15% 0.87 +16%
--------------- ---------- ---- --- ---------- ---- --- ---------- --- -----
-- Q3 2026 was second full quarter of financial results contributed by Oral
Health segment following March 1, 2026 acquisition of Oral Science Inc.:
-- $7.8 million sales
-- $1.6 million EBITDA1
-- $1.2 million NIAT (before $0.83 million amortization expense on
acquired intangible assets)
-- Q3 2026 consolidated EBITDA1 margin: 28% to sales
-- YTD 2026 consolidated EBITDA1 margin: 26% to sales (27% to sales -
adjusted for one-time acquisition costs)
-- Return on Average Equity for the trailing twelve months ('TTM') ended
September 30, 2026 was 23%, increasing from 22% for TTM September 30,
2025
-- During YTD 2026, repurchased and cancelled a total of 326,500 common
shares under a Normal Course Issuer Bid (NCIB)
-- Paid quarterly cash dividends of $0.055 per common share on March 13,
2026, June 15, 2026, and September 15, 2026
-- Subsequent to quarter-end:
-- Repaid remaining $2 million balance of acquisition debt on October
1, 2026
-- Declared subsequent cash dividend of $0.055 per common share to be
paid on December 15, 2026
"Our recently acquired Oral Health business continued to perform well in Q3 2026, its second full quarter of operations as part of BioSyent," commented Mr. René Goehrum, President and CEO of BioSyent. "When combined with our existing pharmaceutical brands, the Oral Science product catalogue gives us a broad platform for continued future growth, both in Canada and internationally. With combined operating cash flows of $6.0 million in Q3 2026, we were able to deploy $1.7 million in share buybacks under our ongoing Normal Course Issuer Bid and $0.6 million in dividends during the quarter while continuing to invest in our brands, including Thyconvi(R) , as we prepare to launch this product in Canada in the first quarter of 2027. Additionally, we have fully repaid our remaining acquisition debt of $2.0 million, leaving us with a clean balance sheet and strong cash position to take advantage of future opportunities and to hedge against future risks. I look forward to reporting on our continuing progress in 2027."
The CEO's presentation on the Q3 2026 Results is available at the following link: www.biosyent.com/investors/
The Company's Interim Unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis for the three and nine months ended September 30, 2026 and 2025 will be posted on www.sedarplus.ca on November 17, 2026.
The Company further announces that its Board of Directors has approved a grant of 2,765 Restricted Share Units ("RSUs") to certain directors of the Company pursuant to the Company's RSU Plan. These RSUs will fully vest within three years on the third anniversary of the applicable grant date.
For a direct market quote for the TSX Venture Exchange and other Company financial information, please visit www.tmxmoney.com.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty healthcare products company focused on acquiring or in-licensing, marketing and distributing innovative pharmaceutical and oral health products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its Pharmaceutical and Oral Health businesses, both in Canada and internationally.
As of the date of this press release, the Company has 11,235,488 common shares outstanding.
BioSyent Inc.
Interim Unaudited Condensed Consolidated Statements
of Comprehensive Income
In Canadian Dollars Q3 2026 Q3 2025 % Change YTD 2026 YTD 2025 % Change
-------------------- ---------------- -------------- ----------
Net Revenues 20,084,587 12,221,804 +64% 53,865,532 33,380,060 +61%
Cost of Goods Sold 6,115,631 2,954,884 +107% 15,758,523 7,863,386 +100%
Gross Profit 13,968,956 9,266,920 +51% 38,107,009 25,516,674 +49%
Operating Expenses
and Finance
Income/Costs 9,561,862 5,617,478 +70% 26,444,506 15,965,050 +66%
Net Income Before
Tax 4,407,094 3,649,442 +21% 11,662,503(++) 9,551,624 +22%
Tax (including
Deferred Tax) 1,546,629 967,102 +60% 3,607,782 2,531,180 +43%
Net Income After Tax 2,860,465 2,682,340 +7% 8,054,721(++) 7,020,444 +15%
Net Income After Tax
% to Net Revenues 14% 22% 15% 21%
EBITDA(1) 5,572,805 3,632,399 +53% 14,188,144 9,594,195 +48%
EBITDA(1) % to Net
Revenues 28% 30% 26% 29%
-------------------- ---------- ---------- ---------- ------------ ---------- ----------
Net of $825,000 amortization expense on intangible assets recognized in acquisition of Oral Science Inc.
++ Net of $1,925,000 amortization expense on intangible assets recognized in acquisition of Oral Science Inc.
BioSyent Inc.
Interim Unaudited Condensed Consolidated Statements
of Financial Position
AS AT September 30, 2026 December 31, 2025 % Change
-------------------- ------------------- ----------
ASSETS
Cash, cash equivalents
and short-term
investments $ 16,016,878 $ 28,651,823 -44%
Trade and other
receivables 7,600,027 4,456,562 71%
Inventory 9,797,612 6,416,204 53%
Prepaid expenses and
deposits 1,912,732 187,977 918%
Derivative asset 17,174 - -
Loans receivable -
current 72,660 80,395 -10%
---------------
CURRENT ASSETS 35,417,083 39,792,961 -11%
---------------- --------------- ------
Long term investments - 3,293,957 -100%
Loans receivable --
non-current - 61,799 -100%
Deferred tax asset 473,452 510,932 -7%
Property and equipment 1,439,965 982,737 47%
Intangible assets 21,695,949 4,797,073 352%
Goodwill 5,928,817 - -
---------------- --------------- ------
TOTAL NON CURRENT
ASSETS 29,538,183 9,646,498 206%
TOTAL ASSETS $ 64,955,266 $ 49,439,459 31%
================ =============== ======
LIABILITIES AND
SHAREHOLDERS' EQUITY
CURRENT LIABILITIES $ 9,806,753 $ 7,215,608 36%
SHORT TERM DEBT 2,000,000 - -
CONTINGENT
CONSIDERATION 5,977,915 - -
NON CURRENT LIABILITIES 626,062 758,345 -17%
TOTAL SHAREHOLDERS'
EQUITY 46,544,536 41,465,506 12%
TOTAL LIABILITIES AND
SHAREHOLDERS' EQUITY $ 64,955,266 $ 49,439,459 31%
================ =============== ======
1. EBITDA is a Non-IFRS Financial Measure. The term EBITDA does not have any
Comments